In the wake of the increase in Current Liabilities in the fourth quarter 2023, Quick Ratio fell to 0.33 below Centogene N V average.

Within Medical Laboratories industry 29 other companies have achieved higher Quick Ratio than Centogene N V in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 2127 to 2602.

Explain Quick Ratio?
How much Cash & cash equivalents CNTG�s has?
What are CNTG�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CNTG/financial-strength

https://api.csimarket.com/api/v1/companies/CNTG/fundamentals

https://api.csimarket.com/api/v1/companies/CNTG/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CNTG Quick Ratio	(Dec 31 2023) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2022) Q4
Y / Y Current Liabilities Change	5.47 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-45.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.33	Subscribe	Subscribe	Subscribe	Subscribe
CNTG's Total Ranking	# 2602	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	33.53 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-1.23 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2023 Company Ranking
Within:	No.
Medical Laboratories Industry	# 30
Healthcare Sector	# 773
Overall Market	# 2602

Quick Ratio Statistics
High	Average	Low
0.9	0.6	0.44
(Dec 31 2022)		(Dec 31 2023)

Financial Statements
Centogene N V 's Current Liabilities	$ 65 Millions	Visit CNTG's Balance sheet
Centogene N V 's Cash & cash equivalent	$ 21 Millions	Visit CNTG's Balance sheet
Source of CNTG's Sales		Visit CNTG's Sales by Geography

Cumulative Centogene N V 's Quick Ratio

CNTG's Quick Ratio for the trailling 12 Months

CNTG Quick Ratio	(Dec 31 2023) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2022) 12 Months
Y / Y Current Liabilities TTM Growth	7.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-46.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.41	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2445	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-16.89 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CNTG Financial Strength Comparisons >> Go to Compare CNTG Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2023 to $64.85 millions, cumulative Quick Ratio decreased to 0.41 below the Centogene N V average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 45 other companies have achieved higher Quick Ratio than Centogene N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 3344 to 4608.

Explain Quick Ratio?
How much Cash & cash equivalents CNTG�s has?
What are CNTG�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 46
Healthcare Sector	# 1145
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.46	0.86	0.44
(Dec 31 2022)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Medical Laboratories Industry	Quick Ratio	Dec 31 2023 MRQ Cash & cash equivalent	Dec 31 2023 MRQ Current Liabilities
Ispecimen inc	0.83	$ 5.033 Millions	$ 6.049 Millions
Radnet Inc	0.80	$ 388.903 Millions	$ 488.055 Millions
Natera Inc	0.79	$ 236.882 Millions	$ 298.962 Millions
Biodesix Inc	0.79	$ 26.284 Millions	$ 33.416 Millions
Medpace Holdings Inc	0.67	$ 245.449 Millions	$ 365.271 Millions
Psychemedics Corporation	0.54	$ 1.964 Millions	$ 3.661 Millions
Mdxhealth Sa	0.50	$ 22.380 Millions	$ 45.018 Millions
Grail Inc	0.47	$ 97.287 Millions	$ 207.192 Millions
Quest Diagnostics Inc	0.41	$ 686.000 Millions	$ 1,662.000 Millions
Renalytix Plc	0.40	$ 5.619 Millions	$ 13.922 Millions
Inotiv Inc	0.35	$ 22.001 Millions	$ 62.563 Millions
Charles River Laboratories International inc	0.33	$ 276.771 Millions	$ 835.964 Millions
Centogene N v	0.33	$ 21.127 Millions	$ 64.855 Millions
Aclarion Inc	0.32	$ 1.021 Millions	$ 3.188 Millions
Iqvia Holdings Inc	0.32	$ 1,496.000 Millions	$ 4,692.000 Millions
Fortrea Holdings Inc	0.22	$ 108.600 Millions	$ 494.400 Millions
Koninklijke Philips Nv	0.20	$ 2,320.808 Millions	$ 11,521.073 Millions
Nrc Health	0.18	$ 6.653 Millions	$ 37.924 Millions
Labcorp Holdings Inc	0.17	$ 536.800 Millions	$ 3,225.200 Millions
Icon Plc	0.12	$ 380.056 Millions	$ 3,203.859 Millions
Capforce Inc	0.10	$ 1.152 Millions	$ 11.422 Millions

Date modified: 2026-09-08T15:11:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.